Knuts, I am not sure you have this correct. I believe Archer has rights for both ARC029 and ARC031 for treatment of Alzheimers. While ARC029 may be straight Nilvadipine, I thought that Archer has/had rights for its use as treatment for Alzheimers. I haven't read anything to suggest that it DOES not also maintain its anti-hypertensive properties. Yes, ARC031 supposedly removes the anti-hypertensive properties and ARC029 is being used in the European trial. That said, I believe that Archer stands to win if ARC029 results are good.
While getting to market of course is ultimately key, it's hard to believe that Mullan's past several years spent with Anatabine was a waste of time. I never saw anything to suggest that Mullan had lost his enthusiasm for anatabine other than the fact that they ran out of $. More and more, it seems that Alzheimers treatment of future appears to be combination of drugs vs. one holy grail.
News 
Market Data 
Discover 
AI
